Abbott Laboratories (NYSE: ABT) closed at $114.88, with a recent decline of 2.75%, amid ongoing interest from analysts. Piper Sandler initiated coverage with an 'overweight' rating and a price target of $131, suggesting a potential upside, while Barclays and Citigroup have also raised their price targets for the stock. Despite challenges from litigation related to necrotizing enterocolitis (NEC), Piper Sandler believes these factors are already priced in, viewing the stock as undervalued. Recent earnings reports showed Abbott exceeding expectations with $1.14 earnings per share and revenues of $10.38 billion, reflecting a solid financial performance. The company's market capitalization stands at approximately $205.53 billion, with a debt-to-equity ratio of 0.38, indicating financial stability. Overall, the consensus rating for Abbott Laboratories remains a 'Moderate Buy' with a target price averaging around $121.80.